(±3,4-Methylenedioxymethamphetamine Selectively Damages Central Serotonergic Neurons in Nonhuman Primates

JAMA: The Journal of the American Medical Association

Volumn 260, Issue 1, 1988, Pages 51-55

  Ricaurte, George A ^a   Forno, Lysia S ^b   Wilson, Mary A ^a   Delanney, Louis E ^c   Irwin, Ian ^c   Molliver, Mark E ^a   Langston, J William ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c CALIFORNIA INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; AMPHETAMINE DERIVATIVE; DRUG DERIVATIVE; SEROTONIN;

CENTRAL NERVOUS SYSTEM; HISTOCHEMISTRY; MONKEY; NONHUMAN; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; ARTICLE; BRAIN; CEBIDAE; DOSE RESPONSE; DRUG EFFECT; FEMALE; MACACA; MALE; METABOLISM; NERVE CELL; NERVE FIBER; NUTRITIONAL DEFICIENCY; PATHOLOGY; RAPHE NUCLEUS;

3,4-METHYLENEDIOXYAMPHETAMINE; AMPHETAMINES; ANIMAL; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HYDROXYINDOLEACETIC ACID; INJECTIONS, SUBCUTANEOUS; MACACA FASCICULARIS; MACACA MULATTA; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NERVE FIBERS; NEURONS; RAPHE NUCLEI; SAIMIRI; SEROTONIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023819569     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1988.03410010059035     Document Type: Article

References (39)

1. Ziporyn T: A growing industry and menace: Makeshift laboratory’s designer drugs. JAMA 1986;256:3061-3063.
2. Baum RM: New variety of street drugs poses growing problem. Chem Engineering News 1985;63:7-16.
3. Hagerty C: ’Designer Drug’ Enforcement Act seeks to attack problem at source. Am Pharm 1985;NS25(10):10.
4. Seymour RB: MDMA. San Francisco, Haight Ashbury Publications, 1986.
5. Barnes DM: New data intensify the agony over ecstasy. Science 1988;239:864-866.
6. Greer G, Tolbert R: Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986;18:319-327.
7. Cotton R: In the matter of MDMA scheduling. Brief including proposed findings of fact and conclusions of law on behalf of Drs Greer and Grinspoon, and Professors Bakalar and Roberts. Dewey, Ballantine, Bushby, Palmer and Wood, 1775 Pennsylvania Ave NW, Washington, DC 20006, Jan 15, 1986.
8. Lawn JC: Schedules of controlled substances: Temporary placement of 3,4-methylenedioxymethamphetamine (MDMA) into Schedule I. Federal Register 1985;50(July 1):23118-23120.
9. Ricaurte GA, Bryan G, Strauss L, et al.: Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 1985;222:986-988.
10. Schmidt CJ, Wu L, Lovenberg W: Methylenedioxymethamphetamine: A potentially neurotoxic amphetamine analogue. Eur J Pharmacol 1985;124:175-178.
11. Stone DM, Stahl DS, Hanson GL, et al.: The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine on monoaminergic systems in the rat brain. Eur J Pharmacol 1986;128:41-48.
12. O’Hearn EG, Battaglia G, De Souza EB, et al.: Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause ablation of serotonergic axon terminals in forebrain: Immunocytochemical evidence. J Neurosci, in press.
13. Schmidt CJ: Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 1987;240:1-7.
14. Commins DL, Vosmer G, Virus R, et al.: Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 1987;241:338-345.
15. Battaglia G, Yeh SY, O’Hearn E, et al.: 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: Quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 1988;242:911-916.
16. Chiueh CC, Markey SP, Burns RS, et al.: N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a parkinsonian syndrome-causing agent in man and monkey, produces different effects in the guinea pig and rat. Pharmacologist 1983;25:131-138.
17. Boyce S, Kelley E, Reavill C, et al.: Repeated administration of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones. Biochem Pharmacol 1984; 33:1747-1752.
18. Burns RS, Chieuh CC, Markey SP, et al.: A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983;80:4546-4550.
19. Langston JW, Forno LS, Rebert CS, et al.: Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 1984;292:390-394.
20. Finnegan KT, Irwin I, DeLanney LE, et al.: 1,2,3,6-Tetrahydro-1-methyl-4-(methylpyrrol-2-yl)pyridine: Studies on the mechanism of action of MPTP. J Pharmacol Exp Ther 1988;242:1144-1151.
21. Wilkening D, Vernier VG, Arthaud LE, et al.: A parkinson-like neurologic deficit in primates is caused by a novel 4-substituted piperidine. Brain Res 1986;368:239-246.
22. Caldwell J, Dring LG, Williams RT: Metabolism of [14C]methamphetamine in man, the guinea pig and the rat. Biochem J 1976, 129:11-21.
23. Kotake C, Heffner T, Vosmer G, et al.: Determination of dopamine, norepinephrine, serotonin and their major metabolic products in rat brain by reverse-phase ion-pair high performance liquid chromatography with electrochemical detection. Pharmacol Biochem Behav 1985;22:85-90.
24. Ricaurte GA, Irwin I, Forno LS, et al.: Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine—induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res 1987;403:43-51.
25. Gerfen C: The neostriatal mosaic: I. Compartmental organization of projections from the striatum to the substantia nigra in the rat. J Comp Neurol 1985;236:454-463.
26. Zhou FC, Azmitia EC: Induced homotypic collateral sprouting of serotonergic fibers in the hippocampus of rat. Brain Res 1984;308:53-62.
27. Forno LS, Langston JW, DeLanney LE, et al.: Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 1986;20:449-455.
28. Manmounas LA, Molliver ME: Dual serotonergic projections to forebrain have separate origins in the dorsal and median raphe nuclei: Retrograde transport after selective axonal ablation by p-chloroamphetamine (PCA). Soc Neurosci Abstr 1987;13:907.
29. Sanders-Bush E, Sulser F: P-chloroamphetamine: In vivo investigations on the mechanism of action of the selective depletion of cerebral serotonin. J Pharmacol Exp Ther 1970;175:419-426.
30. Fuller RW, Perry KW, Molloy B: Reversible and irreversible phases of serotonin depletion by 4-chloroamphetamine. Eur J Pharmacol 1975; 33:119-124.
31. Nichols DE, Lloyd DH, Hoffman AJ, et al.: Effect of certain hallucinogenic amphetamine analogs on the release of [3 H]serotonin from rat brain synaptosomes. J Med Chem 1986;25:530-536.
32. Commins D, Axt K, Vosmer G, et al.: Endogenously produced 5,6-dihydroxytryptamine may mediate the neurotoxic effects of para-chloroamphetamine. Brain Res 1987;403:7-14.
33. Baumgarten HG, Klemm HP, Lachenmayer L, et al.: Mode and mechanism of action of neurotoxic indoleamines: A review and a progress report. Ann NY Acad Sci 1978;305:3-24.
34. Molliver ME, O’Hearn E, Battaglia G, et al.: Direct intracerebral administration of MDA and MDMA does not produce serotonin neurotoxicity. Soc Neurosci Abstr 1986;12:1234.
35. Langston JW, Ballard PA, Tetrud JW, et al.: Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219:979-980.
36. Craighead LW, Stunkard AJ, O’Brien R: Behavior therapy and pharmacotherapy for obesity. Arch Gen Psychiatry 1981;38:763-768.
37. Ritvo ER, Freeman DJ, Geller E, et al.: Effects of fenfluramine on 14 outpatients with the syndrome of autism. J Am Acad Child Psychiatry 1983;22:549-556.
38. Barchas J, Usdin E (eds): Serotonin and Behavior. New York, Academic Press Inc, 1973.
39. Messing RB, Pettibone DJ, Kaufman N, et al.: Behavioral effects of serotonin neurotoxin: An overview. Ann NY Acad Sci 1978;305:480-496.